A consistent finding in research of health services is the gap between availableevidence and clinical practice. It is estimated that30-40% of patients do not receive care according to current scientific evidence.' Contrary to medical practice,very little is known aboutcompliance withpharmacy practice guidelines, particularly those concerning the managementof drug-drug interaction alerts.
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Pharmacists contribute to the detection and prevention of drug therapy-related problems including medication errors, the occurrence of which.has been the subjectof several studiesand part of a public debate about patient safety.s" The negative impactof one type of drug therapy-related problems, drug-drug interactions, on drug related morbidity has beenrepeatedly demonstrated/"
In the Netherlands, 2 guidelines for the management of drug-drug interactions havebeendeveloped andare keptup to date by 2 workinggroupson the basis of published evidence of drug-druginteractions," Thisevidence is transformed into alerts withconcrete recommendations for their management that are incorporated into community pharmacysoftware programs for prescription processing. The software program checks new prescriptions for drug-drug interactions using Author information provided at the endof the text.
BACKGROUND: Pharmacists contribute to the detection and prevention of drug therapy-related problems, including drug-drug interactions. Little is known about compliance withpharmacy practice guidelines for the management of drug-drug interaction alerts. OBJECTIV~: Tomeasure the compliance of community pharmacists with Dutch guidelines for the management of drug-drug interactions and to determine patient-andprescriber-related determinants for noncompliance. METHODS: Sixteen clinically relevant drug-<:trug interactions wereIncluded in the study based on certain described criteria. From June to August 2005, Dutch pharmacists (N = 149)collected alertsoccurring in daily patient carefor these interactions as well as information related to the patient, the alert itself, the prescriber, and the management of the alert. Noncompliance was measured by comparing the management executed by the pharmacy with the national guidelines. RESULTS: Overall compliance withthe guidelines was69.3% (n =423), withlarge differences between the various drug-drug interactions. Male sex (OR 2.25; 95% CI 1.52 to 3.31), oldest age (>75 y; OR 1.97; 95% CI 1.03 to 3.75), and polypharmacy (>7 medications; OR 2.35;95% CI 1.46to 3.80) wereassociated witha higher probability for noncompliance withtheguidelines. Prescriber-related variables had no significant influence on guideline compliance. Substitution of oneof the involved agents, recommended for most of the drug-drug interactions, was executed in a small minority of cases. The outcome of interaction management, such as substitution, dose reduction, or temporary stop of one of the agents, was frequently inconsistent with the guidelines. Compliance rateswere partly influenced by the ultimate decision madeby the prescriber. In that way, pharmacies' compliance was notsolely assessed. However, in only22.5% of the cases wasthe drug-drug interaction presented to the prescriber. CONCLUSIONS: Noncompliance with Dutch guidelines for the management of drug-drug interaction alerts is common in community pharmacies. Further research into underlying reasons for noncompliance is warranted, such as the relation between pharmacist andprescriber in thiscontext. stored information about drugs thatwillbe dispensed simultaneously or havealready beendispensed to the patient. The objective of our study was to determine the compliance rate of community pharmacists to national guidelines for the management of drug-drug interaction alertsas well as patient-andprescriber-related determinants fornoncompliance.
Methods

SETTING AND STUDY POPULATION
All Dutch community pharmacies using the Pharmacom information technology system(N == 791) were invited (once, via mail) to participate in this study, of which 172 (21.7%) responded positively. Ultimately, several pharmaciesdecided not to participate due to heavy workload, and 149(l8.8%)-serving approximately 1.4million patients, which is almost 9% of theDutchpopulation-were included in this study. During a 3 monthperiod (June-August 2005) each participating pharmacy was requested to collect alerts of drug-drug interactions selected for this study (see below) as encountered during routinedaily patient care. The participating pharmacies received a pretested study protocol and the coordinating research center was available for questions throughout the study. The work was conducted in compliance with the requirements of the institutional review board of the Department of Pharmacoepidemiology and Pharmacotherapy, UtrechtUniversity.
SELECTION OFTHE DRUG-DRUG INTERACTIONS
INCLUDED
The Pharmacominformation technology system monitors approximately 300 different types of drug-drug interactions. 1o For our study we selected interactionsthat fulfilled the following criteria: the availableevidence had to be classified as 3 or higher,and the clinical relevance had to be classifiedas C or higher,according to the classification systemdeveloped and maintained by a working group of the Scientific Instituteof Dutch Pharmacists (WINAp) that has been described in detail elsewhere.' In brief,within that classification system, drug-drug interactions are classified on a 6 pointrelevance scale ranging from not serious to very life-threatening (category A-F, respectively) and on a 5 pointevidence scaleranging from not provento very well proven (category 0-4, respectively). In other words, all the included drug-drug interactions had to have potentially harmfulconsequences. An additional criterion was that the managementof these drug-drug interaction alerts according to the national guidelines had to involve the substitution of one of the interacting drugs, which was sometimes presented as the only option and sometimes accompanied by an alternative option.This led to the inclusion of 16drug-drug interactions (Table I ). An important feature of the selected drug-drug interactions is the rela-tivelylow frequency of recurrent alerts,because of the nature of one of the interacting agents (eg, antibiotics, antimycotics, phosphodiesterase type 5 [PDE-5] inhibitors). This decreased the chance that the drug-drug interaction had already been managed in the past for the same patient.
COLLECTION ANDCLASSIFICATION OF DATA
A computer program was developed enabling each pharmacy to extractand collectthe selected drug-drug interaction alerts that hat! occurred duringthe previous week. These data extractions were subsequently sent by the pharmacist to the coordinating research center electronically. On the first day of the week the pharmacist was requested to execute the data extraction and to send the data to the research center. On the third,fourth, and fifth day this procedure was repeated. For each drug-drug interaction alert sent to the research center,a questionnaire was returned to the community pharmacy by email. Subsequently,completed questionnaires were sent to the research center by email,postalmail,or fax.
On the questionnaire form, pharmacists, who had not all been necessarily involved with the drug-drug interaction alert, recorded information related to thepatient (age, sex,estimated current druguse),thealert itself(medicines involved, sameor different prescribers fortheinteracting drugs, type of prescriberof latest prescription [ie, general practitioner or specialist]), and information about the management of that drug-drug interaction alertby the pharmacy. Management was categorized as external action or no external action. External action was definedas an intervention directed at the prescriber, advice given to the patient, or other, suchas communication with the anticoagulation clinic.The specific external action or itsoutcome had to be specified. Someexamplesof specific action taken or theiroutcome include the substitution of oneof theinteracting medicines, a dosechange of one of the interacting medicines, or advice to obtain plasma concentrations (eg,potassium) related to drugs.
In case internal pharmacy procedures did not require external action,the respondent was asked to give reasons for that (eg, recurrent alert or alert already managed in the past). Table I summarizes the management guidelines for the selected drug-drug interactions presented to pharmacists on the computerscreen each time that the drug-drug interactionalertoccurs, as well as in a yearly updated textbook." A working group of Health Base Foundation, a knowledge center closely connected to the Pharmacom information technology system, is responsible for the content of this textbook, which provides background information about severaldrug therapy-related problems,such as drug-drug www.theannals.com
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interactions and drug-disease interactions. Moreover, algorithmic strategies for management are provided, which were used as the gold standard for the evaluation of the management of drug-drug interactions by pharmacists. The comparison between the management output as described on the questionnaires and the guideline was made by one of the authors (HB) and checked by another (TS). The outcome of this comparison was threefold: compliant, noncompliant, or uncertainty as to assessment. Finally, the association between noncompliance with the guidelines and several patient-related characteristics (ie, sex, age, number of drugs in use) and prescriber-related characteris-tics (different prescribers for the interacting drugs, prescriptions prescribed during different consultations, latest prescription from other prescriber [ie, not general practitioner]) was examined.
DATAANALYSIS
Data were analyzed using standard descriptive data analysis (SPSS version 12.0, SPSS Inc., Chicago, IL). Logistic regression analysis was used to estimate the strength of the association between characteristics and noncompliance with the guideline. 
Results
Of the 858 returnedquestionnaires, all cases concerning unjustified alerts(n =97; mostly becausethe first drug had already been stopped) and all alerts missingessentialinformation (n = 17) were excluded from the analysis. The re-maining744 drug-drug interaction alerts were collected by 149 pharmacies, with a range of 1-17 alerts per pharmacy (average 5). The alerts involved an approximately equal numberof males (n =309)andfemales (n =301).The mean ± SO age was 64.5 ± 14.7 years (range2-99). The number of drugs used at the time of the alert was 6.4 ± 3.3 (range 0-22), excluding dermatologic preparations. The frequency of alerts for the 16 included drug-drug interactions (fable 2) was variable, ranging from205 alerts for statin-macrolide interaction to 1 alertfor a St John's wort-digoxin interaction.
One-hundred thirty-four cases (18.0%) couldnot be evaluated because theycontained, primarily, a recurrent alertwithno information aboutits management. Of all alerts for which an assessment was possible (n = 610), pharmacists undertookexternal action in 79.5% (n = 485; Figure 1 ). In case of external action, the prescriber was consultedin 28.2% (n = 137),advice was given to the patient in 72.8%, and another action was undertaken in 14.4%, mainly information giving to the anticoagulation clinic. Twofold actionsoccurredseveraltimes.
Overall compliance with the guideline was 69.3% (n = 423) with highly variable rates depending on the type of interaction.A high compliance rate was found for interactions involving coumarin anticoagulants (92.5% and 95.8%). Compliance was also relatively high for tricyclic antidepressants-terbinafine (90.9%), statins-macrolides Compliance with Guidelines/or Drug-Drug Interactions (89.8%), statins-antimycotics (82.2%), and PDE-5 inhibitors-CYP3A4 inhibitors (75.0%). A relatively low compliance rate was found for interactions involving theophylline(45.0% and 21.6%),digoxin-macrolides (8.9%), and PDE-5 inhibitors-nitrates (2.8%).
The degree of compliance also varied with management recommendations. For alertsfor which substitution was the only proposed managementoption, we found low compliance (9.2%) with the guideline (digoxin-macrolides, methotrexate/trimethoprim/sulfamethoxazole or trimethoprim, carbamazepine-rnacrolides, terfenadine-QT interval prolongingagents, St. John's wort-digoxin). For alertsfor which a clear alternativeoption was possiblein additionto substitution, the compliance amounted to 82.2% (statinsmacrolides, statins-antimycotics, coumarins-trimethoprim/ sulfamethoxazole, theophylline-rnacrolides, coumarins-antimycotics, tricyclic antidepressants-terbinafine, theophylline--quinolones, digoxin-itraconazole).
A temporary stop of one of the agents was executed in 30 cases (4.9%),19 (63.3%)of which were consistentwith the guidelines. Dose adjustment was performedin 17cases (2.8%), of which about half (8 cases) were in accordance with the guidelines.
The associationbetween patient-and prescriber-related variables and noncompliance with the guidelines is presented in Table 3 . Adjustedfor all othervariables, malesex (OR 2.25; 95% CI 1.52 to 3.31), the highest age category (>75 y; OR 1.97;95% CI 1.03 to 3.75), and current use of morethan7 medications (OR 2.35;95% CI 1.46to 3.80) indicatea higher probability for noncompliance concerning the wholegroup of selected drug-drug interactions. Prescriberrelated variables, suchas different prescribers for bothdrugs, were notshown to havesignificant influence on the noncompliant management of drug-drug interaction alerts.
Discussion
To our knowledge, this is the first multicenter study evaluating compliance with national guidelines concerning the management of drug-drug interaction alerts in com-munity pharmacies. The overall compliance rate amounted to 69.3%.The degree of compliance varied with the nature of the drug-drug interaction, patient characteristics, and the natureof the recommended management actions in the guidelines.
The degree of and variation in noncompliance withclinical guidelines in our study matches the outcomes of studies concerning medical practitioners' compliance with di- agnosticor therapeutic guidelines. I ,l1,12 However,it is questionable whether this issue concerning pharmacists' compliance can be fully compared with the outcomes of other professionals. An important difference in our study on drug-drug interactions is that pharmacists must sometimes present the problem with some managementoptions to the prescriber, who ultimately decides on the management of the drug-drug interaction. In our study,pharmacists directly discussed the problem with the prescriber in 22.5% of the cases (n = 137); the compliance rate of these cases was lower (56.2%; n =77) than the average compliance rate in the study (69.3%; n = 423).
There were considerable differences in the quality of the compliant as well as the noncompliant management of pharmacists, which we describe to some extent and illustrate by using examples from this study. Compliant management can imply a rigorous intervention, meaning, for instance, contact with the prescriber as well as communication with the patient and with a substitution of one of the interacting drugs as an outcome.However,compliantmanagementcan also imply no action,for example, in case of a I day course of fluconazole (interaction: coumarins-antimycotics). The same applies to noncompliant interventions. We found superfluous interventions, such as, a warning to the anticoagulation clinic in case of a I day course of fluconazole combined with a coumarin anticoagulant. However, we also found interventions that could be considered potentially doubtful or even potentially negative concerning patient outcomes. Examples were a temporary stop of digoxin use and a temporary stop of theophylline use. Finally, it must be emphasized that some noncompliant outcomesof interventions made by pharmacists,which were mostly in concordance with the prescriber,were certainly realistic: low dosage of digoxin with relatively young age, rise of serum concentration assessed as not problematic because the physician was just about to increase the dosage (carbamazepine), substitution of terbinafine tablet by terbinafine creme.
There are several possible reasons for guideline noncompliance. We cannot exclude that the relation with the prescriber might have affected the intervention. Substitution of one of the interacting drugs was executed in a limited number of cases, even when substitution was the only proposed intervention. Perhaps many pharmacists find substitutionof one of the interacting drugs a difficultand timeconsuming type of management, because it requires intervention toward the prescribing physician. In other studies, interprofessional barriers have been identified concerning the relationship betweencommunity pharmacists and physiclans," In a majorityof cases, more easily applicablemanagement options were preferred, such as a warning to the anticoagulation clinic,temporary stop of a statin,or dose reductionof one of the medicines, mostlywithoutinterference of the prescriber. Nevertheless, a Dutch study revealed that Compliance with Guidelinesfor Drug-Drug Interactions pharmacists and general practitioners largely agree on the surveillancerole that a pharmacist should fulfill." In addition,we observed thatin several instances the prescriber ultimately decided not to change one of the prescribed medicines as recommended. It is an intriguing question whetherthis is associated with the decision frequently made by physicians to override drug-drug interaction alerts15 and/or with a lack of professional persuasiveness of the pharmacist. Continued scientific inquiry is neededregarding pharmacists' and physicians' attitudes and behaviorand the quality of their communication regardingdrug-drug interactionguidelines and management.
Patient characteristics may contribute to noncompliance as well, but our finding of a higher probability of noncompliance for some patient variables, such as male sex, older age, and polypharmacy, is hard to explain. We would have expected more vigilance concerning this drug therapy-related problem in elderly patients with complex pharmacotherapy and being at higher risk. Concerning polypharmacy, a similar finding has been reported by Halkinet al," in a study about preventingdrug interactions. The paradox between what was expected and what was found regarding the relationship between intervention and risk factor needs further exploration. A similar paradox has been described elsewhere as the treatment-risk paradoxconcerning the relative undertreatment with lipid-lowering therapy of high-risk elderly patients." In another study, concerning the relative undertreatment of heart failure patients at highestrisk, it has been described as the risk-treatment mismatch,"
LIMITATIONS OFTHE STUDY
First, the participating pharmacies constituted a voluntary sample, which may have resulted in a positive selection bias concerning the performance of pharmacies. The participating pharmacies all used the Pharmacom operating system, which is used by about 45% of Dutch pharmacies. The guidelines for this system are produced by the Health Base Foundation, which was described in the Methods section. The other Dutch pharmacies use other software programs, but all use the guideline system produced and maintained by another working group not described in this article, Therefore, there is the problem concerning a potential issue of reduced external validity concerning all Dutch pharmacies, but we have no information suggesting a lower or higher quality of pharmacies using the Pharmacom system. Secondly, it may be possible that some drug-drug interactionalerts were not selected or reported. Pharmacists were free to extract data every week, send them to the research center, and finally fill in and return the questionnaires. The burden of a high workload as a consequence of participation in this research project and/or in the pharmacy and the holiday season in the Netherlands resulted in a varied participation of pharma-
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The AnnalsofPharmacotherapy • 2007 December, Volume 4/ • 2029 cies (range 1-17 drug-drug interaction alerts per pharmacy). In other words, some pharmacies may have affected the results more than others. A certain-to our opinion, low-degree of recall bias should not be ignored. It is well known that Dutch pharmacies document the management of a drug-drug interaction and other alerts, for instance, on prescription papers. Pharmacies using the Pharmacom system have an electronic documentation system in which the management of a drug-drug interaction can be described as well. Repeated testing could have influenced pharmacy management of drug-drug interactions. The frequency of most of the included drug-drug interactions, however, is low; only for some was a considerable number found. However, the average number of returned questionnaires was 5 per pharmacy (range 1-17). In combination with a study period of 3 months, we consider this issue to be a minor limitation. A certain degree of underreporting is also possible, because over-the-counter drugs, such as St John's wort, are seldom recorded in Dutch pharmacies and thus will not contribute to drug-drug interaction alerts. Nevertheless, this drug-drug interaction was included since all criteria were fulfilled. However, there is a low risk of not detecting drug-drug interactions because of a low degree of fragmented prescription filling in the Netherlands." Dutch patients are in general loyal to one pharmacy, leading to rather complete medication records. Another limitation is the fact that the compliance rates are partly influenced by the ultimate decision made by the prescriber. In that way, pharmacies' compliance was not solely assessed. However, as described above, in only 22.5% of the cases was the drug-drug interaction problem presented to the prescriber. Finally, in this cohort a relatively low occurrence was found for several drug-drug interactions, meaning that the estimation of compliance rates for these drug-drug interactions is less accurate.
Conclusions
Overall compliance with Dutch guidelines for the management of drug-drug interactions was about 70%, with large differences between the various drug-drug interactions. Male sex, oldest age, and polypharmacy (>7 medications) were associated with a higher probability for noncompliance. Some prescriber-related variables had no significant influence on guideline compliance. Substitution of one of the involved agents, recommended for most of the drug-drug interactions,was executed in a minority of cases. The outcome of interaction management, such as substitution, dose reduction, or temporary stop of one of the agents, was frequently inconsistent with the guideline. Compliance rates were partly influenced by the ultimate decision made by the prescriber. In that way, pharmacies' compliance was not solely assessed. However, in only 22.5% of the cases was the drug-drug interaction problem presented to the pre-scriber. Further research into underlying reasons for noncompliance is warranted, such as the relationship between pharmacist and prescriber in this context. We thank all pharmacistswho participated in the study.Specialthanks to Rohini van Exel, pharmacystudent,for her support in collectingthe data and some preliminaryresearch. Speciallhanksto PharmaPartners company, especially EricHid· dink PharmD and MartijnNieuwhof, for their supportto start this study and for developing a special computer program, enabling eachpharmacy to extractandcollect the selected drug-drug interactions. Thanksalsoto Martine Kruijtbosch MScfor her help in developing the database.
EXTRAcro ANTECEDENTES: Los farmaceuticos contribuyen a la detecci6n y prevenci6n de problemas relacionados con los medicamentos, como las interaceiones farmacol6gicas (IF) . No existe muchainfonnaci6nsobre la obediencia a las recomendaciones paragestionar las alertasde IF. oBJETlvos: Cuantificar la obediencia de las farmacias comunitarias a las recomendaciones holandesas paragestionar las IF y detenninar los factores relacionados con el paciente y con el facultativo que conllevan a la desobediencia. METOOOS: En el estudiose incluyeron 16IF clfnicamente relevantes seleccionadas segiin ciertoscriterios descritos. Desdejunio-agostode 2005, farmacias holandesas (n = 149)recopilaron las alertasobservadas en la atenci6n diariaal paciente dirigidaespecialmentea estas interacciones,junto con la infonnaci6n relacionada con el paciente, con la propiaalerta,con el facultative, y la gesti6nde la alerta.Para cuantificarla desobediencia, se compar6la gesti6nlIevada a cabo por la farmaciacon la dictadapor las recomendaciones nacionales. RESULTADOS Compliancewith Guidelinesfor Drug-Drug Interactions el facultativo no mostraron ninguna influencia significativa sobreesta obediencia. S610 en la menorpartede los casas se lIev6 a cabo la sustituci6n de uno de los farmacos irnplicados, medida recomendada para la mayoria de las IF.Frecuentemente, el desenlace de la gesti6nde la interacci6n, como la sustituci6n de un medicamento, la reducci6n de la dosis0 la interrupci6n temporal de unode los medicamentos, no coincidfa con las recomendaciones. Lastasas de obediencia estaban detenninadas en partepor la decision final que tomabael facultativo. En este sentido,la obediencia de las farmacias no se valoro en solitario. No obstante,s610 se present6 el problema de IF al facultativo en el22.5% de los casos. CONCLUSIONES: La desobediencia a las recornendaciones holandesas es cormln en las farmacias comunitarias. Se debenestudiarcon mayor profundidad las razones subyacentes de esta desobediencia, como la relaci6n entreel farmaceutico y el facultativo en este contexto. RESULTATS: Dansl'ensemble.Ies reglesont ere respectees dans 69,3% des cas (n = 423). Les patients de sexe mascu\in (rapport de coles [RC]: 2.25; IC 95% 1.52a 3.31),d'age pluseleve (>75ans)(RC 1.97; IC 95% 1.03a3.75),et avec une polypharmacie (>7 medicaments) (RC 2.35; IC 95% 1.46a3.80)ont ete associes arisquepluselevede noneonformite aux regles.Les variables reliesau prescripteur n'ont pas demontre d'influencesur les resultats, La substitution d'un des medicaments irnpliques, recommandee dans la plupartdes 1M,n'a ete execuiee que dans une minorite des cas. Les gestesposestelsque la substitution, la reduction de la dose, I'arret temporaire d'un des medicaments etaient frequemment non en conformite avec les \ignesdirectrices. Le tauxde conformite etait influence par la decision ultimedu prescripteur, ce qui a affecteIe tauxde conformiteen pharmacie. Cependant, seulement 22.5%des cas d'IM ont ete presentes au prescripteur. CONCLUSIONS: La nonconformite aux \ignesdirectrices portantsur les 1M est courante dans les pharmacies communautaires en Hollande. D'autres etudessont necessaires afin de comprendre les causessous-jacentes, notamment la relation entre Ie prescripteur etle pharmacien dansce contexteprecis.
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